NYSE
BSX
Last Price
US $51.83
KEY FIGURES
MKT CAP
$77.0B
EPS
TTM
$2.48
PEG
TTM
0.43x
P/E
TTM
20.88x
P/S
TTM
3.65x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
14.90%
Return on equity
ROIC: 10.57%
Valuation History
19.9X
Price to Earnings
EV/EBITDA: 15.0X
Cash flow
Profit margin
15.16%
(FY vs FY)
EBITDA Y/Y
27.55%
(FY vs FY)
Cash flow Y/Y
26.44%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $51.83
-29.17%
Default assumptions
EBITDA Multiple
Fair Value
Market $51.83
-79.53%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Boston Scientific Corporation cash flow to debt ratio of 36.51% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial stability - Healthy cash flow growth.
Boston Scientific Corporation's free cash flow has increased 38.30% from $2.65G last year to $3.66G, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Boston Scientific Corporation's debt to equity ratio is 0.51, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Boston Scientific Corporation's debt has decreased relative to shareholder equity from 0.51 last year to 0.51 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Boston Scientific Corporation has a net debt to EBITDA ratio of 2.03x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Boston Scientific Corporation's interest coverage ratio of 12.41 indicates that earnings with good margin can cover interest payments on company debt
Financial stability - Profit margin growth.
Boston Scientific Corporation's profit margin has increased (57.76%) in the last year from 11.07% to 17.47%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Boston Scientific Corporation's short-term assets of $8.79G exceed its short-term liabilities of $5.44G
Increasing performance - ROA.
Boston Scientific Corporation's return on assets of 8.11% is higher than the 5.00% threshold, indicating efficient asset utilization
Decreasing performance - Absolute return on equity.
Boston Scientific Corporation's return on equity of 14.90%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
Boston Scientific Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Boston Scientific Corporation had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Boston Scientific Corporation has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Boston Scientific Corporation has a free cash flow yield of 4.75%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Boston Scientific Corporation's yearly earnings has increased 55.66% since last year from $1.85G to $2.89G, signaling increasing performance
Increasing performance - Healthy revenue growth.
Boston Scientific Corporation's yearly revenue has increased 19.87% since last year from $16.75G to $20.07G, signaling increasing performance
Increasing performance - ROIC.
ROIC 10.57% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
Boston Scientific Corporation's 3-year revenue CAGR of 16.54% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Boston Scientific Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Boston Scientific Corporation had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Boston Scientific Corporation is overvalued relative to its fair value price of 36.71 based on Discounted Cash Flow model
Undervalued - Earnings yield.
Boston Scientific Corporation has an earnings yield of 4.79%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Boston Scientific Corporation is overvalued relative to its fair value price of 10.61 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Boston Scientific Corporation has an EV/EBITDA ratio of 17.13x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Boston Scientific Corporation has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Boston Scientific Corporation has a price-to-book ratio of 3.04x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Boston Scientific Corporation has a price-to-sales ratio of 3.65x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue